Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review

Rongyu Liu Xinlin He Wanying Bao Zhengyu Li a Department of Gynecology and Obstetrics,West China Second University Hospital,Sichuan University,Chengdu,People's Republic of Chinab Ministry of Education,Key Laboratory of Birth Defects and Related Diseases of Women and Children,Sichuan University,Chengdu,People's Republic of ChinaRongyu Li is a graduate student majoring in Obstetrics and Gynecology at Sichuan University. His special interest include in Immunotherapy of ovarian cancer and the mechanism by which radiotherapy affects immunotherapy.Xinlin He is a graduate student majoring in Obstetrics and Gynecology at Sichuan University. Her special interest include in Organoid orientation of ovarian cancer and HPV vaccine therapy.Wanying Bao is a graduate student majoring in Obstetrics and Gynecology at Sichuan University. Her special interest include in the mechanism of development and targeted therapy of ovarian cancer.Zhengyu Li MD,is the professor and deputy director of Obstetrics and Gynecology Department of West China Second Hospital of Sichuan University,an expert with outstanding contributions of the Sichuan Provincial Health and Family Planning Commission,and an academic and technical leader of the Sichuan Provincial Health and Family Planning Commission. He has won awards such as the Sichuan Provincial Youth Science and Technology Award and the First Prize of the Ministry of Education Science and Technology Progress Award,has authored (and coauthored) over 60 peer-reviewed scientific articles,and has extensive research experience in the fields of gynecological benign and malignant tumors and embryo implantation.
DOI: https://doi.org/10.1080/21645515.2024.2396710
2024-08-29
Human Vaccines & Immunotherapeutics
Abstract:Human papillomavirus (HPV) has been linked to the development of various cancers, including head and neck, cervical, vaginal, penile, and anal cancers. The development of therapeutic vaccines against HPV-positive tumors is crucial for protecting individuals already infected with HPV, preventing tumor progression, and effectively treating the disease. The HPV therapeutic peptide-based vaccines demonstrate specificity and safety advantages by targeting specific epitopes while minimizing the risk of allergic or autoimmune reactions. However, HPV therapeutic peptide-based vaccines typically lack immunogenicity and frequently fail to induce effective immune responses. Therefore, there is a need for more effective approaches to improve the immunogenicity of HPV peptide-based vaccines. Here, we review relevant research and possible uses for increasing the immunogenicity and therapeutic efficacy of HPV peptide-based vaccines through combined therapy and improved delivery strategies. Additional research is necessary to validate the application of combination therapy and delivery strategy modifications as standard treatment approaches for HPV therapeutic peptide-based vaccines.
immunology,biotechnology & applied microbiology
What problem does this paper attempt to address?